Episode Details
Back to EpisodesClinical update with Dr. Daniel Griffin
Description
In his weekly clinical update, Dr. Griffin and Vincent Racaniello are dismayed but not surprised by poll results suggesting most Americans doubt vaccine safety, that the head of the CDC and NIH delayed release of a report on the safety of the COVID-19m vaccine, how Nature works to spread disease without the help of the lab and the about face of the Trump administration to nominate a pro-vaccine candidate for CDC director, before Dr. Griffin then deep dives into the measles outbreak, recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, how the influenza vaccine may attenuate stroke and acute cardiac disease following virus infection, PEMGARDA authorized use for certain immunocompromised individuals where to find PEMGARDA, how to access and pay for Paxlovid, how the COVID-19 pandemic was a 'negative' for one's mortality where to go for answers about long COVID-19, potential therapies for the pediatric long COVID population and contacting your federal government representative to stop the assault on science and biomedical research.
Subscribe (free): Apple Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- More Americans doubt vaccine safety than trust it, POLITICO Poll finds (Politico)
- Top C.D.C. Official Delays Report on Covid Shot's Effectiveness (NY Times)
- Vampire bats in Mexico may feed on CWD-positive deer, spreading disease and posing species-jump threat (CIDRAP)
- Emerging risks at the vampire bat–prion interface: implications for wildlife, livestock, and public health (Journal of Mammalogy)
- Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males (JAMA: Oncology)
- Trump Administration Eyes Erica Schwartz to Lead CDC (Wall Street Journal)
- Trump to Nominate Doctor Who Has Publicly Supported Vaccines as C.D.C. Director (NY Times)
-
Listen Now
Love PodBriefly?
If you like Podbriefly.com, please consider donating to support the ongoing development.
Support Us